Press Releases Press Releases Randomized Controlled Trial Confirms Impella CP® Improves Survival in Heart Attack with Cardiogenic Shock April 7, 2024 Learn More Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI May 18, 2023 Read More Johnson & Johnson Completes Acquisition of Abiomed December 22, 2022 Learn More FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial December 21, 2022 Read More First Patients in the World Treated with Impella RP Flex with SmartAssist December 6, 2022 Read More Johnson & Johnson to Acquire Abiomed November 1, 2022 Learn More Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure October 21, 2022 Read More Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support October 13, 2022 Read More Multi-Center, Multi-Society Study of Impella®-Supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77% September 20, 2022 Read More Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% September 19, 2022 Read More Unloading with Impella® for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients September 17, 2022 Read More Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella August 19, 2022 Read More SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes May 19, 2022 Read More World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump April 26, 2022 Read More First Patient in Japan Treated with Impella 5.5® with SmartAssist® April 6, 2022 Read More 1 2 3 4 NPS-2558
